Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 1816 AL 1830

Progress in Modeling Neural Tube Development and Defects by Organoid Reconstruction

Li P, Chen Y.

Neurosci Bull. 2022 Nov;38(11):1409-1419. doi: 10.1007/s12264-022-00896-9. Epub 2022 Jun 26.

Neuroleptic malignant syndrome in a case of extra-pontine myelinolysis: On the horns of dilemma

Arora U, Goel A, Ray A, Vikram NK.

Drug Discov Ther. 2022 Jul 20;16(3):145-147. doi: 10.5582/ddt.2021.01012. Epub 2022 Jun 25.

Empowerment in people with Parkinson's disease: A scoping review and qualitative interview study

Kang E, Friz D, Lipsey K, Foster ER.

Patient Educ Couns. 2022 Oct;105(10):3123-3133. doi: 10.1016/j.pec.2022.06.003. Epub 2022 Jun 9.

Microglia in Parkinson's Disease

Stefanova N.

J Parkinsons Dis. 2022;12(s1):S105-S112. doi: 10.3233/JPD-223237.

Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson's Disease

Williams GP, Schonhoff AM, Sette A, Lindestam Arlehamn CS.

J Parkinsons Dis. 2022;12(s1):S129-S136. doi: 10.3233/JPD-223241.

Effects of Resistance Training on Motor- and Non-Motor Symptoms in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis

Gollan R, Ernst M, Lieker E, Caro-Valenzuela J, Monsef I, Dresen A, Roheger M, Skoetz N, Kalbe E, Folkerts AK.

J Parkinsons Dis. 2022;12(6):1783-1806. doi: 10.3233/JPD-223252.

The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson's Disease: A Mini-Review

Chan GH.

Front Aging Neurosci. 2022 Jun 10;14:895430. doi: 10.3389/fnagi.2022.895430. eCollection 2022.

PINK1/Parkin Pathway Activation for Mitochondrial Quality Control - Which Is the Best Molecular Target for Therapy?

Silvian LF.

Front Aging Neurosci. 2022 Jun 8;14:890823. doi: 10.3389/fnagi.2022.890823. eCollection 2022.

Dural Arteriovenous Fistula as a Reversible Cause of Progressive Parkinsonism and Dementia: A Case Report

Prosperini L, Gentile M, Ricci M, Gerace C, Fabiano S, Stasolla A, Gasperini C, Cotroneo E.

Neurohospitalist. 2022 Jul;12(3):559-562. doi: 10.1177/19418744221098542. Epub 2022 Apr 27.

Mitochondria targeting drugs for neurodegenerative diseases-Design, mechanism and application

Xu J, Du W, Zhao Y, Lim K, Lu L, Zhang C, Li L.

Acta Pharm Sin B. 2022 Jun;12(6):2778-2789. doi: 10.1016/j.apsb.2022.03.001. Epub 2022 Mar 10.

Levodopa-Carbidopa Intestinal Gel may improve treatment-resistant freezing of gait in Parkinson's disease

Shackleford MR, Mishra V, Mari Z.

Clin Park Relat Disord. 2022 Jun 8;7:100148. doi: 10.1016/j.prdoa.2022.100148. eCollection 2022.

Functional amyloids from bacterial biofilms - structural properties and interaction partners

Akbey Ü, Andreasen M.

Chem Sci. 2022 May 6;13(22):6457-6477. doi: 10.1039/d2sc00645f. eCollection 2022 Jun 7.

Editorial: Targeting α-Synuclein in Parkinson's Disease and Multiple System Atrophy

Fellner L, Richter F, Brundin P, Haybaeck J.

Front Neurol. 2022 Jun 10;13:942313. doi: 10.3389/fneur.2022.942313. eCollection 2022.

Cell Non-autonomous Proteostasis Regulation in Aging and Disease

Ferreira JV, da Rosa Soares A, Pereira P.

Front Neurosci. 2022 Jun 9;16:878296. doi: 10.3389/fnins.2022.878296. eCollection 2022.

Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis

Żegleń M, Śladowska K, Kawalec P, Brzostek T.

J Comp Eff Res. 2022 Aug;11(12):889-904. doi: 10.2217/cer-2022-0031. Epub 2022 Jun 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias